CN105400785A - 一种与他莫昔芬耐药性相关的microRNA分子MiR-200a及其应用 - Google Patents

一种与他莫昔芬耐药性相关的microRNA分子MiR-200a及其应用 Download PDF

Info

Publication number
CN105400785A
CN105400785A CN201510869409.1A CN201510869409A CN105400785A CN 105400785 A CN105400785 A CN 105400785A CN 201510869409 A CN201510869409 A CN 201510869409A CN 105400785 A CN105400785 A CN 105400785A
Authority
CN
China
Prior art keywords
tamoxifen
breast cancer
mir
resistance
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510869409.1A
Other languages
English (en)
Inventor
张健
李梦阳
张媛
陈苏宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fourth Military Medical University FMMU
Original Assignee
Fourth Military Medical University FMMU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fourth Military Medical University FMMU filed Critical Fourth Military Medical University FMMU
Priority to CN201510869409.1A priority Critical patent/CN105400785A/zh
Publication of CN105400785A publication Critical patent/CN105400785A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Abstract

本发明公开了一种与他莫昔芬耐药性相关的microRNA分子MiR-200a及其应用，属于肿瘤生物治疗领域。本发明公开了一种与他莫昔芬耐药性相关的microRNA分子MiR-200a，其核苷酸序列如SEQ.ID.NO.1所示。MiR-200a具有在ER阳性乳腺癌他莫昔芬耐药细胞中低表达、在ER阳性乳腺癌他莫昔芬敏感细胞中高表达的特性，是一种新的乳腺癌他莫昔芬耐药标志物。因此，本发明为设计抗乳腺癌他莫昔芬耐药药物提供了新的靶点，并以此为依据，用以设计和开发直接针对乳腺癌他莫昔芬耐药的新药。本发明公开的MiR-200a具有促进乳腺癌细胞耐药的生物学功能及作用机制，为有效逆转乳腺癌他莫昔芬耐药及提高乳腺癌的临床化疗效果提供有效途径。

Description

一种与他莫昔芬耐药性相关的microRNA分子MiR-200a及其应用
技术领域
本发明属于肿瘤生物治疗领域，涉及一种与他莫昔芬耐药性相关的microRNA分子MiR-200a及其应用。
背景技术
乳腺癌是女性最常见的恶性肿瘤之一，其高发病率严重威胁着女性的身体健康。目前，以他莫昔芬为基础的内分泌疗法对雌性激素受体(ER)阳性乳腺癌患者的疗效具有重要意义。
他莫昔芬是目前ER阳性乳腺癌治疗的临床一线用药，该药为雌二醇竞争性拮抗剂，通过与雌二醇竞争性结合雌激素受体，减弱雌激素受体介导的肿瘤增殖转移相关的信号转导，从而达到治疗肿瘤的作用。但在肯定治疗效果的同时，不得不承认肿瘤细胞产生耐药现象是ER阳性乳腺癌转移和复发的重要原因，他莫昔芬出现的耐药现象是限制其临床疗效的主要原因。
发明内容
本发明的目的在于提供一种与他莫昔芬耐药性相关的microRNA分子MiR-200a及其应用。
本发明是通过以下技术方案来实现：
本发明公开了一种与他莫昔芬耐药性相关的microRNA分子MiR-200a，MiR-200a的核苷酸序列如SEQ.ID.NO.1所示。
本发明还公开了上述的microRNA分子MiR-200a作为乳腺癌他莫昔芬耐药标志物的应用。
所述的microRNA分子MiR-200a在雌性激素受体阳性乳腺癌他莫昔芬耐药细胞中低表达。
所述的microRNA分子MiR-200a在雌性激素受体阳性乳腺癌他莫昔芬敏感细胞中高表达。
本发明还公开了上述的microRNA分子MiR-200a在制备针对乳腺癌他莫昔芬耐药的药物中的应用。
本发明还公开了上述的microRNA分子MiR-200a作为设计抗乳腺癌他莫昔芬耐药的药物靶点的应用。
与现有技术相比，本发明具有以下有益的技术效果：
本发明公开了一种与他莫昔芬耐药性相关的microRNA分子，为MiR-200a，其核苷酸序列如SEQ.ID.NO.1所示。MiR-200a具有在ER阳性乳腺癌他莫昔芬耐药细胞中低表达、在ER阳性乳腺癌他莫昔芬敏感细胞中高表达的特性，是一种新的乳腺癌他莫昔芬耐药标志物。因此，本发明为设计抗乳腺癌他莫昔芬耐药的药物提供了新的靶点，并以此为依据，用以设计和开发直接针对乳腺癌他莫昔芬耐药的新药。本发明公开的MiR-200a具有促进乳腺癌细胞耐药的生物学功能及作用机制，为有效逆转乳腺癌他莫昔芬耐药及提高乳腺癌的临床化疗效果提供有效途径。
附图说明
图1为构建MCF-7他莫昔芬耐药细胞系(MCF-7/TR)，通过细胞增殖-毒性实验检测MCF-7/TR对他莫昔芬的耐药能力。
图2为Real-timePCR检测MCF-7/TR及MCF-7亲本细胞中MiR-200a的表达水平。
图3为细胞增殖-毒性实验检测转染MiR-200a后构建的MCF-7/TR细胞对他莫昔芬的耐药能力。
图4为细胞增殖-毒性实验检测转染MiR-200aantagomiR后乳腺癌MCF-7亲本细胞对他莫昔芬的耐药能力。
具体实施方式
下面结合具体的实施例对本发明做进一步的详细说明，所述是对本发明的解释而不是限定。
他莫昔芬在乳腺癌的治疗过程中发挥着重要作用，但出现的耐药现象是限制其临床疗效的主要原因。明确新的microRNA在乳腺癌细胞他莫昔芬耐药中的生物学功能和机制为有效提高乳腺癌的临床疗效提供新的生物靶标选择。
本发明公开了一种肿瘤耐药microRNA分子，为MiR-200a，其核苷酸序列为CAUCUUACCGGACAGUGCUGGA。
本发明还公开了MiR-200a作为设计抗乳腺癌他莫昔芬耐药药物靶点的用途，以及MiR-200a在乳腺癌他莫昔芬耐药性的临床诊断中的应用，以及根据这一靶点设计出的药物。
1、构建MCF-7他莫昔芬耐药细胞系(MCF-7/TR)
采用高浓度短时间他莫昔芬冲击法诱导MCF-7/TR耐药细胞株。取对数生长期的MCF-7细胞约个10^7，接种于直径为10cm的培养皿中，待细胞生长稳定后加入终浓度为10μmol/L的他莫昔芬，2-3天换液1次，每次换液后加入等浓度的他莫昔芬。经过2月的培养后，通过有限稀释法获得单克隆的乳腺癌MCF-7他莫昔芬耐药细胞，并在7d无药物干预下扩增细胞。为了维持MCF-7/TR耐药细胞株的耐药性，细胞长期在终浓度为2μmol/L的他莫昔芬的培养液中培养。
2、检测MCF-7亲本细胞及MCF-7/TR细胞中miR-200a的表达量
1)引物设计
hsa_miR_200a_PrimerForwardPrimer(20μM)：
CATCTTACCGGACAGTGCTGGA。
2)细胞总RNA提取
A.整个RNA提取过程需要带口罩和手套，并且在冰上操作，防止RNA降解。
B.将细胞用预冷的PBS洗涤两次，每组样品加入1mL提前预冷的Trizol，用加样枪反复吹打。
C.在冰上放置5min，保证细胞充分的裂解。
D.将上步处理的样品转入DEPC水处理过的1.5mLEP管中，加入200μL氯仿，上下颠倒充分混匀摇匀，静置5min使其分层。4℃12000rpm离心15min，离心后吸取约500μL上层液体至新的1.5mLDEPC水处理过的EP管中。
E.加入与D步等体积的异丙醇，上下颠倒充分混匀。
F.室温静置10min后，4℃12000rpm离心15min，弃上清。加入1mL乙醇，可见有白色沉淀析出。将洗涤后的乙醇洗干净，后倒置在滤纸上，静止一段时间，用20μLDEPC水溶解。
G.定量提取的RNA：取2μLRNA溶解于98μLTEbuffer中，用紫外分光光度计测定其A260和A280值，分析RNA的纯度。
3)细胞总mRNA反转录
取提取好的5μg总RNA，用TaKaRa公司的PrimeScriptRT逆转录试剂盒进行反转录实验，反应体系如表1所示：
表1
反应条件为：37℃，15min；85℃，5sec。
4)进行RealtimePCR实验
A.使用SYBRPremixExTaqIITaKaRa试剂盒进行实验；
B.按表2所示反应体系加样至每孔；
表2
C.采用两步法行PCR：1cycle，30s；95℃，5s；60℃，34s。
D.用GraphpadPrism5软件进行数据分析并制表。
3、细胞增殖-毒性实验检测细胞转染后的耐药指数研究
当乳腺癌MCF-7/TR细胞处于生长活跃状态时，于转染前一天接种到六孔板中，经16～18小时后，细胞总面积达到50～80％左右，将5μlLipofectamine2000加入500μl无血清培养基中放置15分钟，每5μlMiR-200amimics及对照NC(终浓度为20μM)也分别加入500μl无血清培养基室温预孵育15分钟，后混合均匀，室温放置20分钟。6小时后更换为10％胎牛血清培养液，转染48小时后分别消化离心各组细胞分别按每孔8000个细胞接种于96孔板培养箱预培养24小时(在37℃，5％CO2的条件下)，待细胞贴壁后给予不同浓度他莫昔芬处理，将96孔板在培养箱孵育4天后，更换新鲜培养液后向每孔加入10μL噻唑蓝溶液，将培养板在培养箱内孵育2.5小时后用酶标仪测定在450nm处的吸光度。
乳腺癌MCF-7亲本细胞中接种于6孔板，细胞密度1×105个细胞，加入2mL无抗生素的10％胎牛血清培养液过夜，细胞贴壁密度融合达50％-60％时，6孔板(每孔)取5μl浓度为20μM的化学合成寡聚核苷酸MiR-200aantagomiR/阴性对照antagomiRNC，加入500μl无血清培养基稀释，静置15分钟；取5μLLipofectamine2000加入500μl无血清培养基静置5分钟，混合均匀室温再放置20分钟形成转染复合物后加入6孔板中，细胞培养箱中培养，转染6h-8h后换液。48小时后细胞增殖-毒性实验测定转染antagomiR及阴性对照inhibiorNC后MCF-7细胞对他莫昔芬的耐药性变化。
结果显示：
1)细胞增殖-毒性实验检测筛选得到的MCF-7他莫昔芬耐药细胞系他莫昔芬耐药能力
细胞增殖-毒性实验结果显示，相对于MCF-7亲本细胞，MCF-7/TR细胞在高浓度的他莫昔芬处理下存活率更高，耐药能力显著增强，参见图1。
2)Real-timePCR检测乳腺癌MCF-7亲本及MCF-7/TR细胞中MiR-200a的表达水平
通过Real-timePCR检测分析乳腺癌MCF-7亲本和MCF-7/TR细胞中MiR-200a的表达水平，参见图2，结果显示，相对于亲本细胞，MiR-200a在乳腺癌MCF-7/TR细胞中表达显著降低。由此推测MiR-200a的表达有可能与乳腺癌他莫昔芬耐药能力相关。
3)细胞增殖-毒性实验检测转染MiR-200amimics后对乳腺癌MCF-7/TR细胞他莫昔芬耐药能力的影响
为明确MiR-200a是否对乳腺癌细胞的他莫昔芬耐药能力有所影响，通过将化学合成的MiR-200amimics转染至MCF-7/TR细胞，使MiR-200a在MCF-7/TR细胞中表达增高并比较加药处理后细胞的他莫昔芬耐药能力，参见图3，结果显示，转染MiR-200a组的细胞他莫昔芬耐药能力显著低于其他组细胞。
4)细胞增殖-毒性实验检测转染MiR-200aantagomiR后对乳腺癌MCF-7细胞他莫昔芬耐药能力影响
将化学合成的MiR-200aantagomiR/NCantagomiR转染至乳腺癌MCF-7细胞中，使得MiR-200a在MCF-7中表达降低。参见图4，结果显示，相对于对照组细胞，转染MiR-200aantagomiR组的细胞对他莫昔芬的耐药性显著增强，进一步证明了MiR-200a的与乳腺癌细胞他莫昔芬耐药能力密切相关。
综上所述，随着microRNA在肿瘤发生和耐药性获得过程中的研究不断深入，本发明通过生物信息学技术预测可能参与乳腺癌细胞他莫昔芬耐药的microRNA分子，基于分子克隆相关技术构建慢病毒载体，利用乳腺癌细胞感染microRNA病毒后明确的生物学功能变化，筛选出明确参与乳腺癌细胞他莫昔芬耐药的microRNA，并进一步分析验证筛选得到的MiR-200a促进乳腺癌细胞耐药的生物学功能及作用机制，为有效逆转乳腺癌他莫昔芬耐药及提高乳腺癌的临床化疗效果提供有效途径。

Claims (6)

1.一种与他莫昔芬耐药性相关的microRNA分子MiR-200a，其特征在于，MiR-200a的核苷酸序列如SEQ.ID.NO.1所示。
2.权利要求1所述的microRNA分子MiR-200a作为乳腺癌他莫昔芬耐药标志物的应用。
3.如权利要求2所述的应用，其特征在于，所述的microRNA分子MiR-200a在雌性激素受体阳性乳腺癌他莫昔芬耐药细胞中低表达。
4.如权利要求2所述的应用，其特征在于，所述的microRNA分子MiR-200a在雌性激素受体阳性乳腺癌他莫昔芬敏感细胞中高表达。
5.权利要求1所述的microRNA分子MiR-200a在制备针对乳腺癌他莫昔芬耐药的药物中的应用。
6.权利要求1所述的microRNA分子MiR-200a作为设计抗乳腺癌他莫昔芬耐药的药物靶点的应用。
CN201510869409.1A 2015-12-01 2015-12-01 一种与他莫昔芬耐药性相关的microRNA分子MiR-200a及其应用 Pending CN105400785A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510869409.1A CN105400785A (zh) 2015-12-01 2015-12-01 一种与他莫昔芬耐药性相关的microRNA分子MiR-200a及其应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510869409.1A CN105400785A (zh) 2015-12-01 2015-12-01 一种与他莫昔芬耐药性相关的microRNA分子MiR-200a及其应用

Publications (1)

Publication Number Publication Date
CN105400785A true CN105400785A (zh) 2016-03-16

Family

ID=55466546

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510869409.1A Pending CN105400785A (zh) 2015-12-01 2015-12-01 一种与他莫昔芬耐药性相关的microRNA分子MiR-200a及其应用

Country Status (1)

Country Link
CN (1) CN105400785A (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106148538A (zh) * 2016-08-09 2016-11-23 山东大学 microRNA标志物组及其在制备评价乳腺癌化疗敏感性试剂盒中的应用
CN108753966A (zh) * 2018-06-07 2018-11-06 浙江省人民医院 一种非编码RNA分子lnc-DC在预测乳腺癌他莫昔芬耐药中的应用
CN114164280A (zh) * 2021-12-30 2022-03-11 黑龙江省科学院高技术研究院 Ddit3作为乳腺癌耐药检测靶点的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101842484A (zh) * 2007-09-14 2010-09-22 俄亥俄州立大学研究基金会 人外周血微泡中的mirna表达和其用途
EP2695942A1 (en) * 2012-08-07 2014-02-12 Pelican Health Limited microRNAs in therapy and diagnostic of cancer
CN104120185A (zh) * 2014-08-01 2014-10-29 常州百代生物科技有限公司 利用血清miRNA量的变化比诊断肝癌的方法及试剂盒

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101842484A (zh) * 2007-09-14 2010-09-22 俄亥俄州立大学研究基金会 人外周血微泡中的mirna表达和其用途
EP2695942A1 (en) * 2012-08-07 2014-02-12 Pelican Health Limited microRNAs in therapy and diagnostic of cancer
CN104120185A (zh) * 2014-08-01 2014-10-29 常州百代生物科技有限公司 利用血清miRNA量的变化比诊断肝癌的方法及试剂盒

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TISSA T. MANAVALAN等: "Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells", 《CANCER LETT.》 *
TISSA T. MANAVALAN等: "Reduced Expression of miR-200 Family Members Contributes to Antiestrogen Resistance in LY2 Human Breast Cancer Cells", 《PLOS ONE》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106148538A (zh) * 2016-08-09 2016-11-23 山东大学 microRNA标志物组及其在制备评价乳腺癌化疗敏感性试剂盒中的应用
CN106148538B (zh) * 2016-08-09 2019-10-22 山东大学 microRNA标志物组及其在制备评价乳腺癌化疗敏感性试剂盒中的应用
CN108753966A (zh) * 2018-06-07 2018-11-06 浙江省人民医院 一种非编码RNA分子lnc-DC在预测乳腺癌他莫昔芬耐药中的应用
CN114164280A (zh) * 2021-12-30 2022-03-11 黑龙江省科学院高技术研究院 Ddit3作为乳腺癌耐药检测靶点的应用

Similar Documents

Publication Publication Date Title
Sun et al. Increased expression of lncRNA HULC indicates a poor prognosis and promotes cell metastasis in osteosarcoma
Tsang et al. Long non‐coding RNA HOTTIP is frequently up‐regulated in hepatocellular carcinoma and is targeted by tumour suppressive miR‐125b
Tao et al. Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer
Xue et al. HOXA11-AS: a novel regulator in human cancer proliferation and metastasis
Wu et al. Functions and roles of long-non-coding RNAs in human nasopharyngeal carcinoma
Cheng et al. Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma
Chen et al. A genetic variant in the promoter region of Toll-like receptor 9 and cervical cancer susceptibility
Wang et al. Circular RNA expression in oral squamous cell carcinoma
Wang et al. A common genetic variation in the promoter of miR-107 is associated with gastric adenocarcinoma susceptibility and survival
CN105400785A (zh) 一种与他莫昔芬耐药性相关的microRNA分子MiR-200a及其应用
CN108753969A (zh) 长链非编码rna在肝细胞癌诊疗中的应用
Gong et al. A novel circular RNA (hsa_circRNA_102336), a plausible biomarker, promotes the tumorigenesis by sponging miR-515-5p in human bladder cancer
Han et al. A novel microRNA signature predicts vascular invasion in hepatocellular carcinoma
CN105441449A (zh) 一种与他莫昔芬耐药性相关的microRNA分子MiR-141及其应用
Tian et al. MicroRNA-497-5p is downregulated in hepatocellular carcinoma and associated with tumorigenesis and poor prognosis in patients
Liao et al. Reflections on the role of Malat1 in gynecological cancer
Bai et al. Up-regulation of long non-coding RNA LOXL1-AS1 functions as an oncogene in cervical squamous cell carcinoma by sponging miR-21
Llovet et al. Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma
Agaram Update on myogenic sarcomas
CN105412944A (zh) miR-451a细胞在非小细胞肺癌中的作用
Nazarizadeh et al. MicroRNA-154: a novel candidate for diagnosis and therapy of human cancers
Wang et al. Association of LAPTM4B gene polymorphism with nasopharyngeal carcinoma susceptibility in a Chinese population
Liu et al. LINC00313 regulates the metastasis of testicular germ cell tumors through epithelial-mesenchyme transition and immune pathways
Lee et al. Analysis of lung cancer-related genetic changes in long-term and low-dose polyhexamethylene guanidine phosphate (PHMG-p) treated human pulmonary alveolar epithelial cells
Xu et al. miR-340 exerts suppressive effect on retinoblastoma progression by targeting KIF14

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160316